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Abstract 
Background: Current therapy for inflammatory diseases is glucocorticoids (GCs) 
either as monotherapy or combined with immunosuppressive medications. The 
side effects of the GCs are often limiting, therefore new therapeutic options are 
urgently required. Biological agents such as rituximab, tocilizumab or anti TNF 
antibodies showed promising results. Hence, we investigated the impact of 
biologicals on the prescription of GCs, clinical improvement and laboratory 
findings. 
Method: We performed a retrospective analysis of the medical history of 44 cases 
of severe or relapsing inflammatory diseases, which were not appropriately 
controlled with standard immunosuppressive therapy. Our focus was on GCs 
dosage, clinical improvement and inflammatory parameters.  
Results: Rituximab treatment (n = 18) resulted in a significant decrease in the daily 
prednisone dosage and also a clear decrease in CRP levels and leucocyte counts. 
Another group of 10 patients were treated with anti TNF antibodies (adalimumab   
n = 8, infliximab n = 1, etanercept n = 1) and displayed an obvious decrease in the 
daily prednisone dosage as well as a significant decrease of the CRP level. 
Treatment of patients (n = 5) with tocilizumab showed a pronounced reduction of 
the daily prednisone dosage, whereas the decrease in CRP levels as well as 
leucocyte counts was less distinct. Patients treated with anti interleukin 1 
antibodies (anakinra n = 10, canakinumab n = 1) showed also a pronounced 
decrease of the daily prednisone dosage, whereas again the reduction of CRP 
levels and the leucocyte counts was less distinct. Furthermore, 34 of 39 patients 
(87%, 5 no data) had a clinical improvement of their symptoms after 24 weeks of 
treatment. 
Conclusion: We demonstrate that the GCs dosage can be reduced and the 
laboratory inflammation parameters tend to normalization under the treatment with 
biological agents. Biologicals should be considered if a patient with severe or 
relapsing inflammatory diseases cannot be treated with the standard 
immunosuppressive therapy or exerts severe side effects. 
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1.  Introduction 
Systemic vasculitides represent a heterogeneous group of inflammatory 
diseases commonly affecting the arterial and/or venous blood vessels. 
Characteristic for the vasculitis manifestations are on the on hand generalized 
symptoms such as weight loss or fever, but on the other hand also specific 
symptoms that strictly depend on the localization of the affected blood vessels. 
Due to the chronic inflammation an injury or occlusion the affected blood vessels 
can occur, which leads to a hypoperfusion and finally damage of the affected 
organ system. Crucial for the correct diagnosis is the particular patient history as 
well as the clinical findings. A biopsy of the suspicious lesion, radiological methods 
such as angiography or duplex-ultrasound, and blood analysis, e.g. for specific 
autoantibodies, are often needed to confirm the diagnosis (1). An annual incidence 
of 40 to 54 cases per one million persons is reported (2) and it seems that the 
incidence depends on age, season and location (3). 
According to the latest Chapel-Hill classification from 2012 it has to be 
distinguished between small vessel vasculitis, medium vessel vasculitis and large 
vessel vasculitis. A further group is represented by secondary vasculitis, such as 
rheumatoid vasculitis, drug-induced vasculitis or virus infection associated with 
vasculitis (HBV, HCV or HIV) (4) (5). Without treatment, vasculitis can become a 
life-threatening condition exerting disabling disease manifestations. An induction 
treatment followed by a long-term maintenance therapy is needed to control the 
disease.  
Systemic autoimmune disorders represent a heterogeneous group of 
inflammatory diseases which can affect multiple organ systems (e.g. Systemic 
Lupus Erythematosus (SLE), Sjögren's syndrome, etc.). General symptoms such 
as fever, fatigue, weight loss or night sweats and specific symptoms depending on 
the effected organ system are typical. Determining for the correct diagnosis are the 
patient history, clinical findings and blood analysis (e.g. for specific 
autoantibodies).  
The prevalence of SLE is 50 per 100’000 and mostly women are affected 
(90% of the patients) (6). Increased inflammatory disease activity and progressive 
organ damage result in substantial morbidity and mortality (6, 7). Disease flares 
may occur even with what seems to be the ideal treatment at the moment (8). 
Autoinflammatory diseases encompass a group of disorders characterized 
by recurrent episodes of inflammation without a known trigger (e.g. TRAPS). They 
share a genetic background and are caused by mutations in genes coding proteins 
directly involved in the biology of inflammasome, in which interleukin 1 (IL-1), a 
proinflammatory cytokine and important mediator of the systemic inflammatory 
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response, plays a crucial role. In contrast to autoimmune diseases, no high titer 
autoantibodies or specific-T or B-cell autoreactivity are detected. 
To date, the most common therapy for inflammatory diseases are 
glucocorticoids (GCs) either as monotherapy or combined with certain 
immunosuppressive medications such as cyclophosphamide (CYC), azathioprine 
(AZA) or methotrexate (MTX) (3). However, therapy failure and disease relapses 
are common (9, 10) (37). An additional limitation of this treatment is the cumulative 
toxicity and side effects of immunosuppressants like CYC or MTX (11). Another 
limitation of the treatment are the various side effects of the GCs such as gain of 
weight, Cushing's syndrome, arterial hypertension, gastrointestinal bleeding, 
gastrointestinal ulcers, depression, cataract, osteoporosis, diabetes mellitus, 
opportunistic infections and a risk factor for thromboembolism (12-20). The side 
effects depend on different factors like the duration of the treatment, dosage, 
daytime of the administration and the application form. Due to the described side 
effects it is a major goal in treatment to reduce to GCs dosage as fast and as much 
as possible.  
Based on the above described problems with current therapy approaches, 
it is obviously of great interest on the one hand to obtain an additional treatment 
option for patients with therapy failure and/or disease relapses as well as to reduce 
the needed GCs dosage to maintain remission. In the last few years so-called 
biologicals (e.g. rituximab (RTX): anti CD20 antibody, tocilizumab (TCZ): anti 
interleukin 6 receptor antibody, infliximab (IFX)/adalimumab (ADA): anti TNF 
antibodies) were tested for the use in patients featuring a severe clinical disease 
course (3).  
Previous case series and observational studies have demonstrated an 
effect of biological treatment in inflammatory diseases. Nevertheless, large RCTs 
are required to clarify to role of biological agents in the treatment of vasculitis (3). 
However, also these new biologicals can exert severe side effects and 
some special examinations are required before their use. For RTX it is necessary 
to screen the patients for hepatitis B, because it can exacerbate or reactivate the 
infection. For IFX/ADA it is important to screen for latent tuberculosis, because 
TNF inhibitors can reactivate tuberculosis, and also for viral hepatitis. Rare cases 
of a perforated diverticulitis under the treatment with TCZ where reported. Hence, 
status post diverticulitis or intestinal perforation seems to be a relative 
contraindication.   
All in all, data about the use of these novel therapeutic agents in patients 
with inflammatory diseases are promising, but nevertheless rare and still 
unanswered questions about the effectiveness and safety of the biological agents 
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remain. Therefore, our study aims to analyze the impact of a treatment with 
biological agents on the clinical course, a possible reduction of the dosage of GCs 
as well as safety issues in patients suffering from inflammatory diseases.  
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2.  Method 
We retrospectively analyzed 44 cases of patients receiving biologic agents 
as off-label treatment for inflammatory diseases at the Division of Internal 
Medicine, University Hospital Zurich, Switzerland between 2006 and 2014. The 
biologicals used were: rituximab (anti CD20 antibody), adalimumab (anti TNF 
antibody), infliximab (anti TNF antibody), etanercept (anti TNF antibody), 
tocilizumab (anti interleukin 6 receptor antibody), anakinra (anti interleukin 1 
receptor antibody) and canakinumab (anti interleukin 1beta antibody).  
A detailed review of each patient’s medical record was undertaken, 
focusing on the medical treatment (before and concurrent to the biological 
treatment), secondary diagnoses, blood chemistry and hematology values, the 
concurrent medication and disease outcome during and/or after treatment. The 
data was collected on the first biological agent administration, six weeks and 24 
weeks later. 
The statistical analysis was performed using ANOVA (One-way Analysis of 
Variance) in the program GraphPad InStat. The figures were created with 
KaleidaGraph. 
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3.  Case Presentation and Results 
3.1  Anti CD20 Antibody: Rituximab (RTX) 
18 patients (mean age 50 years, 6 male, 12 female) were treated with 
rituximab. Thereof, seven patients had granulomatosis with polyangiitis (GPA), one 
eosinophilic granulomatosis with polyangiitis, four SLE, three Sjögren’s syndrome, 
one microscopic polyangiitis, one myasthenia gravis and one suspected ORL 
manifestation of an IgG4 related disease. For further information please refer to 
table 1 (Appendix). 
As induction therapy in patients with vasculitis, RTX is given 1000 mg two 
infusions of 1000 mg each two weeks apart or 375 mg/m2/week for four weeks 
(21). For maintenance of remission, RTX should then be administered every six 
month in a dosage of 500 mg (22, 23). All of our patients were treated according to 
this scheme.  
In patients with RTX treatment the baseline prednisone dosage at RTX 
treatment start was 29.3 mg/d. After a period of six weeks, the mean prednisone 
dose decreased to 20.6 mg/d and a further reduction down to 6.8 mg/d was noted 
after 24 weeks of RTX treatment (figure 1a). Figure 1b shows the individual 
prednisone dosage reduction during the 24 weeks of RTX treatment. A downward 
trend of the prednisone dosage was noticeable, although one patient needed an 
increased dosage after six weeks. The numbers of the patients refer to table 1 
(Appendix).  
At the beginning of the RTX treatment the baseline CRP was 9.7 mg/l. Within 
the first six weeks of treatment there was a reduction to 5.1 mg/l and after 24 
weeks in total it decreased to 3.7 mg/l as shown in figure 1c. Fig. 1d depicts for 
each patient the course of CRP, whereas a general downward trend can be 
observed.  
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Fig. 1a: Mean prednisone dosage reduction during treatment with rituximab (*p < 
0.0016 vs. week 0). 
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Fig. 1b: Individual prednisone dosage reduction during treatment with rituximab 
(patient numbers refer to Tab. 1). 
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Fig. 1c: Mean CRP concentration reduction during treatment with rituximab. 
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Fig. 1d: Individual CRP concentration reduction during treatment with rituximab 
(patient numbers refer to Tab. 1). 
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The mean baseline of leucocytes count was 8.2 G/l at RTX treatment start. It 
decreased to 8.0 G/l after six weeks of treatment. A further reduction to 7.1 G/l was 
noted after 24 weeks of treatment with RTX (figure 1e). Figure 1f shows the 
leucocytes count as a function of time for each patient. 
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Fig. 1e: Mean leucocytes count during treatment with rituximab. 
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Fig. 1f: Individual leucocytes count during treatment with rituximab (patient 
numbers refer to Tab. 1). 
 
The secondary diagnoses are listed in figure 2. It is noticeable that diseases of the 
metabolic syndrome e.g. arterial hypertension, diabetes mellitus, obesity and 
hyperuricemia and other side effects of the GCs such as depression, osteopenia or 
s.p. venous thromboembolism are very common.   
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Fig. 2: Secondary diagnoses of the patients treated with rituximab. 
 
3.2  Anti TNF Antibodies: Adalimumab (ADA), Infliximab (IFX), Etanercept 
(ETN) 
10 patients (mean age 45, 4 male, 6 female) were treated with either one of 
three different anti TNF antibodies or TNF inhibitors, respectively (adalimumab n = 
8, infliximab n = 1, etanecerpt n = 1). In this group, two patients suffered from 
Behcet's disease, two Takayasu's arteriitis, one undifferentiated small vessel 
vasculitis, one Henoch-Schoenlein purpura, one polyarteriitis nodosa, one 
ulcerative leukocytoclastic vasculitis, one recurrent polychondritis and one tumor 
necrosis receptor-associated periodic syndrome (TRAPS). For further information 
please refer to table 2 (Appendix). 
ADA was given 40 mg every two weeks. The normal dosage of IFX is 5 
mg/kg body weight in week zero, two and six as an induction therapy and then 
every six weeks as a maintenance therapy. The patient who was treated with ETN 
received 25 mg twice a week.  
In patients with ADA treatment the baseline prednisone dosage was 35.9 mg/d at 
the treatment beginning. Six weeks later there was a reduction down to 23.4 mg/d 
and after 24 weeks of ADA treatment a further decrease to 9.7 mg/d (fig. 3a). 
Figure 3b shows the individual prednisone dosage during the 24 weeks of ADA 
treatment. A downward trend of the prednisone dosage was observable, although 
one patient needed an increased dosage after six weeks and another patient 
received an increased dosage after 24 weeks. The numbers of the patients refer to 
table 2 (Appendix). 
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Fig. 3a: Mean prednisone dosage during treatment with adalimumab. 
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Fig. 3b: Individual prednisone dosage reduction during treatment with adalimumab 
(patient numbers refer to Tab. 2). 
 
The CRP baseline at ADA treatment start was 23.3 mg/l. There was a significant 
reduction (0 vs 6 weeks, p<0.05) down to 4.1 mg/l after six weeks and a further 
decrease to 2.0 mg/l after 24 weeks (0 vs 24 weeks, p<0.05) with ADA treatment 
(figure 3c). The individual CRP level is shown in figure 3d. After 24 weeks of ADA 
treatment all patients had a maximum CRP of 5 mg/l. 
At treatment start with ADA the baseline of the leucocytes count was 8.8 G/l. It 
increased to 9.1 G/l after six weeks but after 24 weeks of ADA treatment the 
leucocytes count decreased to 8.4 G/l as shown in figure 3e. While some patients 
displayed a decrease of the leucocytes count, others showed an increase (Figure 
3f).   
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Fig. 3c: Mean CRP concentration during treatment with adalimumab (* p < 0.05 vs. 
week 0, ** p < 0.05 vs. week 0). 
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Fig. 3d: Individual CRP concentration reduction during treatment with adalimumab 
(patient numbers refer to Tab. 2). 
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Fig. 3e: Mean leucocytes count during treatment with adalimumab. 
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Fig. 3f: Individual leucocytes count during treatment with adalimumab (patient 
numbers refer to Tab. 2). 
 
Only one patient was treated with IFX and one with ETN within the investigated 
time period. The GCs dosage of the patient who received IFX was still at 20 mg/d 
after six weeks. The patient died before the next follow up. 
The patient who was treated with ETN received prednisone 60 mg/d in week zero 
and was then lost to follow up. 
The secondary diagnoses are listed in figure 4. It is again noticeable that 
diseases of the metabolic syndrome such as diabetes mellitus and obesity and the 
other side effects of the GCs treatment (e.g. depression, osteoporosis, venous 
thromboembolism) are common. 
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Fig. 4: Secondary diagnoses of the patients treated with anti TNF antibodies. 
 
3.3  Anti Interleukin 6 Receptor Antibody: Tocilizumab (TCZ) 
Five patients (mean age 58, 1 male, 4 female) received tocilizumab. 
Thereof, two patients suffered from temporal arteriitis, one from large vessel 
vasculitis, one from Takayasu’s arteritis and one from Castleman’s disease. 
The dosage of TCZ was 8 mg/kg body weight every four weeks. In patients 
treated with TCZ the baseline prednisone dosage was 11.5 mg/d at treatment 
beginning. A reduction to 7.5 mg/d six weeks later and a further decrease down to 
4.9 mg/d was observable after 24 weeks (figure 5a). The individual prednisone 
dosage is shown in figure 5b. The downward trend was noticeable, even though 
one patient needed an increased dose after six and 24 weeks. The numbers of the 
patients refer to table 3 (Appendix). 
At the beginning of TCZ treatment the baseline CRP was 6.9 mg/l and it 
decreased to 4.6 mg/l after six weeks. A slight increase up to 5.8 mg/l was 
observed after 24 weeks (figure 5c). Figure 5d shows the individual CRP levels. A 
downward trend of the CRP occurred, although one patient had an elevated CRP 
after six weeks and another patient after 24 weeks. 
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Fig. 5a: Mean prednisone dosage during treatment with tocilizumab. 
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Fig. 5b: Individual prednisone dosage during treatment with tocilizumab (patient 
numbers refer to Tab. 3). 
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Fig. 5c: Mean CRP concentration during treatment with tocilizumab. 
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Fig. 5d: Individual CRP concentration during treatment with tocilizumab (patient 
numbers refer to Tab. 3). 
 
The baseline of leucocytes count was 10.8 G/l at TCZ treatment start. 
There was a reduction down to 8.0 G/l after six weeks and a further reduction to 
7.9 G/l after 24 weeks was observable (figure 5e). The individual leucocytes count 
is shown in figure 5f. A downward trend of the leucocytes count occurred even 
though two patients had an increased leucocytes count after 24 weeks.   
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Fig. 5e: Mean leucocytes count during treatment with tocilizumab. 
 
The secondary diagnoses are listed in figure 6. The side effects of the GCs 
such as osteopenia, osteoporosis and diabetes mellitus or arterial hypertension 
were observed. 
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Fig. 5f: Individual leucocytes count reduction during treatment with tocilizumab 
(patient numbers refer to Tab. 3). 
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Fig. 6: Secondary diagnoses of the patients treated with tocilizumab. 
 
3.4  Interleukin 1 Blockade: Anakinra (ANK) and Canakinumab (CKN) 
11 patients (mean age 38, 1 male, 10 female) were treated with interleukin 
1 blockade (anakinra n = 10, canakinumab n = 1). Thereof, four patients had 
juvenile idiopathic arthritis, two periodic fevers with aphthous stomatitis, 
pharyngitis, and adenitis (PFAPA) syndrome, two chronic systemic inflammation, 
one Behcet's disease, one neutrophilic dermatosis and one tumor necrosis 
receptor-associated periodic syndrome (TRAPS). For further information please 
refer to table 3 (Appendix). 
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At the beginning of ANK treatment the baseline prednisone dosage was 
16.3 mg/d. After six weeks a reduction to 4.0 mg/d and a further reduction down to 
3.4 mg/d after 24 weeks was observable (figure 7a). The individual prednisone 
dosage is shown in figure 7b. A downward trend of the prednisone dosage was 
visible, although one patient needed an increased dosage after 24 weeks. The 
numbers of the patients refer to table 3 (Appendix). 
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Fig. 7a: Mean prednisone dosage during treatment with anakinra. 
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Fig. 7b: Individual prednisone dosage during treatment with anakinra (patient 
numbers refer to Tab. 3). 
 
The baseline CRP at treatment start with ANK was 25.7 mg/l. There was a 
reduction to 11.4 mg/l after six weeks, but after 24 weeks it increased to 15.5 mg/d 
(figure 7c). Figure 7d shows the individual CRP. While most of the patients 
exhibited a reduction of the CRP, others displayed a slight increase after six weeks 
and one patient had a pronounced increase. 
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Fig. 7c: Mean CRP concentration during treatment with anakinra. 
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Fig. 7d: Individual CRP concentration reduction during treatment with anakinra 
(patient numbers refer to Tab. 3). 
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Fig. 7e: Mean leucocytes count during treatment with anakinra. 
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The baseline of the leucocytes count at ANK treatment start was 9.8 G/l. A 
decrease to 7.8 G/l after six weeks and a further reduction down to 7.7 G/l after 24 
weeks was found (figure 7e). The individual leucocytes count is shown in figure 7f, 
where some patients displayed a decrease others an increase. 
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Fig. 7f: Individual leucocytes count reduction during treatment with anakinra 
(patient numbers refer to Tab. 3). 
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Fig. 8: Secondary diagnoses of the patients treated with anakinra and 
canakinumab. 
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One patient with TRAPS was treated with CKN. At treatment start he 
received prednisone 20 mg/d but no blood chemistry or hematology analysis was 
done. No information about the medication after six and 24 weeks was available. 
Six weeks later the leucocytes count was 6.6 G/l and the CRP was 2.8 mg/l. The 
leucocytes count increased to 8.4 G/l after 24 weeks. No information about the 
CRP was recorded. 
The secondary diagnoses are listed in figure 8.  
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4.  Discussion 
This study demonstrates that biological agents combined with GCs reduce 
the daily GCs dosage necessary to control inflammation and vasculitis symptoms 
and, therefore, finally reduce GC related side effects. This is supported by the fact 
that the laboratory findings of the inflammation parameters for most of the patients 
trend towards normalization. 
The necessary daily prednisone dosage is significantly reduced under RTX 
treatment after 24 weeks. Furthermore the mean CRP level is reduced to a 
physiological level. It seems likely that the decrease of the leucocytes count is due 
to the reduction of the daily GCs dosage as well as the declining inflammation, 
which is caused by the biological agents. All seven patients with GPA achieved 
remission after 24 weeks of treatment with RTX. Similar results were found by 
Cartin-Ceba et al. (2012) (24). Two out of four patients with SLE had a clinical 
improvement after 24 weeks. Diaz-Lagares et al. (2011) described a therapeutic 
response of the renal function in 67% of the patients (25). Two out of three patients 
with Sjögren’s syndrome showed a clinical improvement after 24 weeks. The third 
patient was lost to follow up. A significant improvement of fatigue and global health 
was shown by Dass et al (2008) (26). However, a multicenter RCT from 2014 
could not verify those findings (27). In general, RTX was well tolerated, and no 
serious adverse effect was observable during treatment. Similar results were found 
by Cartin-Ceba et al. (2012)(24). 
In this study the daily GCs dosage was reduced after six and 24 weeks of 
treatment with ADA. In addition, the CRP level significantly decreased after six and 
24 weeks (p<0.05). The leucocytes count was in the physiological range during the 
study. One of two patients with Behcet’s disease showed a clinical improvement 
after 24 weeks. Perra et al. (2012) (28) described a complete or partial 
improvement in 17 of 19 patients with Behcet’s disease (89%). Two patients with 
Takayasu’s arteriitis were treated with ADA and both showed a clinical 
improvement after 24 weeks. Novikov et al. (2013) (29) reported that 89% of the 
patients treated with anti TNF therapy in Takayasu’s arteriitis resulted in an 
improvement of clinical and laboratory signs. In this study ADA was well tolerated 
and similar results were found by Perra et al. (28) as well as Novikov et al. (29). 
Furthermore no side effects were observed in all studies. Even after a long term 
anti TNF therapy, the risk of an infectious complication was low (29). 
In this study after six and 24 weeks of treatment with TCZ, the daily GCs 
dosage was reduced. The CRP level decreased after six, but increased slightly 
after 24 weeks compared to week six. The leucocytes count was elevated in the 
beginning of the study but then decreased to the physiological range. The reason 
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for this decrease was most likely due to the facts that – on the one hand – the daily 
GCs dosage had been reduced and – on the other hand – the inflammation was 
controlled by the biological agents. Two patients with temporal arteriitis were 
treated with TCZ. They both had a clinical improvement after 24 weeks. Loricera et 
al. (2015) (30) reported that 19 of 22 patients with temporal arteriitis treated with 
TCZ achieved a clinical improvement (86%). A patient with Takayasu’s arteriitis 
was treated with TCZ. The patient achieved a clinical improvement after six weeks, 
however no improvement after 24 weeks. Osman et al. (2015) (31) reported in 
their case series that all three patients with Takayasu’s arteriitis treated with TCZ 
markedly improved at the three months follow up. One patient with Castleman’s 
disease was treated with TCZ. Six and 24 weeks after treatment begin, a clinical 
improvement was observed. Nagao et al. (2014) (32) published two case reports of 
patients with Castleman’s disease. They were both treated with TCZ and became 
symptom-free after 8 to 10 weeks. However, 15 to 22 weeks after treatment start, 
they both had a relapse and the TCZ therapy was discontinued. They both 
received RTX and no further relapse was reported. Otherwise, Kawabata et al. 
(2013) (33) presented the case of a patient with Castleman’s disease, who was 
successfully treated with TCZ.  
Four patients with juvenile idiopathic arthritis were treated with ANK. Three 
of the four patients displayed a clinical improvement after six and 24 weeks. The 
other patient achieved no clinical improvement. Pardeo et al. (2015) (34) reported 
that after six months of treatment with ANK 14 of 25 (56%) patients (median age 
5.8 years) with JIA met the criteria for inactive disease. Two patients with PFAPA 
syndrome were treated with ANK. One had a clinical improvement after six and 24 
weeks, the other did not improve after six weeks and was then lost to follow up. A 
recent study suggests that treatment with ANK reduces the duration of an acute 
flare (35). One patient with TRAPS was treated with CKN and showed an 
improvement after 24 weeks of treatment. La Torre et al. (2015) (36) authored a 
case report of a patient with TRAPS treated with CKN. After the three and nine 
month follow-up, the TRAPS disease manifestations were still controlled. 
The strength of this study is that it describes a collective of patients 
suffering from inflammatory diseases with respect to their response to biological 
treatment. This novel therapeutic options seem to be promising. However, data 
about its efficacy and safety are still rather rare in the here studied indications. This 
systematic analysis clearly demonstrated the usefulness of these molecules in the 
treatment of inflammatory diseases. Therefore, this study adds importantly to 
establishing novel treatment options in daily clinical practice and contributes to a 
better knowledge about a successful, safe and novel therapy for the treatment of 
inflammatory diseases. 
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The limitation of this study is that it is a retrospective, single center study 
based on the analysis of medical files meaning that the data were not collected in 
a standardized manner and the biological agents were only given to patients with 
severe or relapsing inflammatory diseases. Additionally, the effect of the 
biologicals was not controlled appropriately with the effect of GCs and other 
immunosuppressive agents such as CYC or MTX, in that particular patient 
collective. Moreover, it has to be taken into account that the sample size is low. 
In summary, it can be stated that in this study patients with severe or 
relapsing inflammatory diseases were treated with biologicals. The laboratory 
inflammation parameters, the GCs dosage as well as other laboratory parameters 
were measured within a time period of six months after the first biological 
administration. Despite the above mentioned limitations of this study, we it shows 
that the GCs dosage can be reduced and the laboratory inflammation parameters 
tend to normalization. Therefore, biologicals should always be considered if a 
patient with severe or relapsing inflammatory diseases cannot be treated with the 
standard immunosuppressive therapy. However, further studies are required in 
order to define the possibilities and limitations of this indication for the use of 
biologicals in inflammatory diseases treatment more precisely. 
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Appendix 
 
Table 1: Patient characteristics anti CD20 antibody (rituximab, n = 18) 
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    6 w 24 w  start 6 w 24 w 
1 granulomatosis 
with polyangiitis 
m 44 y y cyclophosphamide, 
prednisone, 
azathioprine, MTX 
prednisone 30mg/d, 
mycophenolic acid 
1,5g/d,  
cyclophosphamide  1.2g 
every 3 week 
prednisone 30mg/d,  
mycophenolic acid  2g/d 
prednisone 7.5mg/d,  
mycophenolic acid  
800mg/d 
2 granulomatosis 
with polyangiitis 
f 50 no 
data 
y cyclophosphamide,  
methylprednisolone, 
prednisone,  
azathioprine, MTX 
prednisone 65mg/d no data prednisone 7.5mg/d, 
MTX 20mg/w 
3 granulomatosis 
with polyangiitis 
m 54 no 
data 
y MTX, prednisone prednisone 60mg/d prednisone 20mg/d, 
azathioprine 150 mg/d 
prednisone 15mg/d, 
azathioprine 150mg/d 
4 granulomatosis 
with polyangiitis 
m 33 y y azathioprine,  
cyclophosphamide, 
MTX, mycophenolic 
acid, prednisone 
prednisone 20mg/d,  
mycophenolic acid 2g/d 
prednisone 20mg/d,  
mycophenolic acid 2g/d  
prednisone 5mg/d,  
mycophenolic acid 2g/d 
5 granulomatosis 
with polyangiitis 
m 38 y y prednisone, MTX,  
azathioprine 
azathioprine  200mg/d azathioprine 200mg/d azathioprine 200mg/d 
6 granulomatosis 
with polyangiitis 
m 62 y y prednisone,  
azathioprine,  
mycophenolic acid, 
MTX 
prednisone 20mg/d, MTX 
10mg/w 
prednisone 15mg/d, 
MTX 20mg/w 
prednisone 10mg/d, 
MTX 20mg/w 
7 granulomatosis 
with polyangiitis 
f 60 y y prednisone prednisone 40mg/d prednisone 7.5mg/d prednisone 5mg/d 
8 systemic lupus 
erythematosus 
f 31 y y none prednisone 40mg/d,  
mycophenolic acid 
1.5g/d,  
hydroxychloroquine 
400mg/d 
prednisone 7.5mg/d,  
mycophenolic acid 3g/d,  
hydroxychloroquine 
400mg/d 
prednisone 5mg/d,  
mycophenolic acid 3g/d,  
hydroxychloroquine 
400mg/d 
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 9 systemic lupus 
erythematosus 
f 53 n n prednisone,  
cyclophosphamide,  
mycophenolic acid,  
azathioprine,  
hydroxychloroquine 
prednisone 20mg/d,  
azathioprine 150mg/d 
prednisone 10mg/d,  
azathioprine 150mg/d 
prednisone 5mg/d,  
azathioprine 150mg/d 
10 systemic lupus 
erythematosus 
f 33 n n prednisone,  
hydroxychloroquine,  
cyclophosphamide,  
azathioprine 
prednisone 40mg/d,  
azathioprine 100mg/d,  
hydroxychloroquine 
200mg/d  
prednisone 80mg/d,  
azathioprine 100mg/d,  
hydroxychloroquine 
200mg/d 
prednisone 20mg/d,  
azathioprine 100mg/d,  
hydroxychloroquine 
200mg/d, imatinib 
200mg/d 
11 systemic lupus 
erythematosus 
f 36 y y prednisone,  
hydroxychloroquine 
prednisone 10mg/d,  
mycophenolic acid 2g/d 
prednisone 10mg/d,  
mycophenolic acid 2g/d 
prednisone 8mg/d,  
mycophenolic acid 2g/d 
12 Sjögren's 
syndrome 
f 52 y no 
data 
prednisone, 
azathioprine 
prednisone 2.5mg/d,  
azathioprine 100mg/d 
prednisone 2.5mg/d,  
azathioprine 100mg/d 
azathioprine 100mg/d, 
hydroxychloroquine 
400mg/d 
13 Sjögren's 
syndrome 
m 64 n y prednisone,  
cyclophosphamide 
prednisone 30mg/d prednisone 30mg/d prednisone 7.5mg/d,  
azathioprine 100mg/d 
14 Sjögren's 
syndrome 
f 71 no 
data 
y prednisone,  
cyclophosphamide,  
azathioprine 
prednisone 15mg/d no data prednisone 7.5mg/d 
15 microscopic 
polyangiitis 
f 69 y y prednisone,  
azathioprine, 
cyclophosphamide,  
mycophenolic acid 
prednisone 60mg/d,  
mycophenolic acid 
150mg/d 
prednisone 50mg/d,  
mycophenolic acid 1g/d 
prednisone 7.5mg/d,  
mycophenolic acid 1g/d 
16 myasthenia gravis f 53 no 
data 
y prednisone, 
azathioprine,  
mycophenolic acid 
mycophenolic acid 2g/d no data mycophenolic acid 1g/d 
17 suspected ORL 
manifestation of an  
IgG4 related 
disease 
f 55 y y prednisone prednisone 10mg/d prednisone 7.5mg/d prednisone 5mg/d 
18 eosinophilic 
granulomatosis 
with polyangiitis 
f 44 y y prednisone,  
cyclophosphamide 
prednisone 65mg/d prednisone 40mg/d prednisone 7.5mg/d 
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Table 2: Patient characteristics anti TNF antibodies (adalimumab, infliximab, etanercept), n = 10 
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1 Behcet's disease m 43 y n prednisone, azathioprine,  
mycophenolic acid,  
cyclophosphamide 
prednisone 
40mg/d,  
mycophenolic acid 
1g/d 
prednisone 
15mg/d,  
mycophenolic acid 
2g/d 
prednisone 
20mg/d,  
mycophenolic acid 
1g/d 
2 Behcet's disease m 31 y y prednisone, azathioprine, 
colchicine 
prednisone 
20mg/d,  
azathioprine 
150mg/d 
prednisone 
10mg/d 
prednisone 
7.5mg/d, 
colchicine 1mg/d 
3 Takayasu's arteriitis f 37 no 
data 
y prednisone,  IFX, MTX prednisone 
7.5mg/d, MTX 
7.5mg/w 
prednisone 
7.5mg/d 
prednisone 
7.5mg/d 
4 Takayasu's arteriitis f 31 n y prednisone, azathioprine prednisone 
30mg/d,  
azathioprine 
100mg/d 
prednisone 
10mg/d,  
azathioprine  
100mg/d 
prednisone 
10mg/d,  
azathioprine 
100mg/d 
5 undifferentiated small 
vessel vasculitis 
f 39 n y azathioprine, prednisone,  
methylprednisolone,  
cyclophosphamide, 
mycophenolic acid 
prednisone 
40mg/d 
prednisone 
50mg/d 
prednisone 
7.5mg/d 
6 Henoch–Schoenlein 
purpura 
f 75 n y prednisone prednisone 
10mg/d 
prednisone 5mg/d none 
7 polyarteriitis nodosa f 33 y y prednisone,  mycophenolic acid,  
azathioprine, MTX,  
methylprednisolone,  
cyclophosphamide 
prednisone 
100mg/d,  
mycophenolic acid 
1g/d 
prednisone 
40mg/d,  
mycophenolic acid 
1g/d 
prednisone 
17.5mg/d,  
mycophenolic acid 
1g/d 
8 ulcerative 
leukocytoclastic 
vasculitis 
f 48 n y prednisone, mycophenolic acid, 
azathioprine, thalidomide, 
melphalan,  cyclophosphamide 
prednisone 
40mg/d,  
mycophenolic acid 
1.5g/d 
prednisone 
50mg/d,  
mycophenolic acid  
1.5g/d 
prednisone 
7.5mg/d,  
mycophenolic acid 
1g/d 
IF
X
 9 recurrent  polychondritis m 75 n - prednisone, azathioprine, MTX prednisone 
20mg/d 
prednisone 
20mg/d 
patient died 
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E
TN
 
10 tumor necrosis factor 
receptor-associated 
periodic syndrome 
(TRAPS) 
m 35 no 
data 
no 
data 
prednisone prednisone 
60mg/d 
no data no data 
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Table 3: Patient characteristics anti interleukin agents (tocilizumab, anakinra, canakinumab), n = 16 
 nu
m
be
r 
di
ag
no
si
s 
se
x 
ag
e 
cl
in
ic
al
 
im
pr
ov
em
en
t 
pr
et
re
at
m
en
t 
co
nc
ur
re
nt
 
m
ed
ic
at
io
n 
TC
Z 
    6 w 24 w  start 6 w 24 w 
1 temporal arteriitis m 69 y y prednisone, MTX prednisone 
12.5mg/d, MTX 
10mg/w 
prednisone 
7.5mg/d 
prednisone 
4.5mg/d 
2 temporal arteriitis f 75 n y prednisone, MTX prednisone 7.5mg/d 
MTX 15mg/w 
prednisone 
10mg/d 
prednisone 
15mg/d, MTX 
15mg/w 
3 large vessel vasculitis f 64 y y prednisone, MTX prednisone 
17.5mg/d, MTX 
20mg/w 
prednisone 
5mg/d, MTX 
20mg/w 
prednisone 
5mg/d, MTX 
20mg/w 
4 Takayasu's arteriitis f 40 y n prednisone, MTX, ADA, IFX prednisone 10mg/d prednisone 
5mg/d 
none 
5 Castleman’s disease f 43 y y prednisone prednisone 10mg/d prednisone 
10mg/d 
none 
A
N
K
 
6 juvenile idiopathic arthritis f 32 n n prednisone prednisone 50mg/d prednisone 
10mg/d 
prednisone 
20mg/d 
7 juvenile idiopathic arthritis f 36 y y prednisone, MTX,  azathioprine prednisone 7.5mg/d prednisone 
5mg/d 
prednisone 
3.5mg/d 
8 juvenile idiopathic arthritis f 32 y y prednisone,  ETN,  
azathioprine 
prednisone 50mg/d prednisone 
7.5mg/d 
none 
9 juvenile idiopathic arthritis f 27 y y prednisone, cyclosporin dexamethasone 
8mg/d 
cyclosporin 
100mg/d 
cyclosporin 
50mg/d 
10 PFAPA syndrome f 23 y y prednisone none none none 
11 PFAPA syndrome f 22 n no 
data 
none none none none 
12 Behcet's disease f 29 n y prednisone, colchicine,  
azathioprine, golimumab 
none none none 
13 chronic systemic 
inflammation 
f 63 n y prednisone, azathioprine prednisone 15mg/d prednisone 
10mg/d 
prednisone 
7.5mg/d 
14 neutrophilic dermatosis f 62 y y prednisone,  colchicine, 
hydroxychloroquine, dapsone, 
cyclosporin 
prednisone 20mg/d none none 
15 chronic systemic 
inflammation 
f 55 n no 
data 
prednisone prednisone 20mg/d, 
colchicine 1mg/d 
prednisone 
7.5mg/d 
no data 
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C
K
N
 
16 tumor necrosis factor 
receptor-associated 
periodic syndrome 
(TRAPS) 
m 35 no 
data 
y ETN prednisone 20mg/d no data no data 
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